Type 2 Pill Reduces Heart Disease-Related Deaths
For the first time, a pill used for treating type 2 diabetes has been shown to reduce the risk of death from heart disease. In a three-year study of 7,020 people with type 2 diabetes who had heart disease at the start of the trial, empagliflozin (Jardiance) cut the risk of heart disease–related death by 32 percent compared with a placebo. There was no difference in the rates of nonfatal heart attack or stroke, however, and researchers are still trying to figure out why. Also unknown: whether the same effect would be seen with other drugs that, like empagliflozin, work by causing glucose to be pulled out of the bloodstream and into the urine, including canagliflozin (Invokana) and dapagliflozin (Farxiga).
Source: The New England Journal of Medicine, published online Sept. 17, 2015